Primary biliary cirrhosis secondary prevention

Primary Biliary Cirrhosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Primary Biliary Cirrhosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Primary biliary cirrhosis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Primary biliary cirrhosis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Primary biliary cirrhosis secondary prevention
CDC on Primary biliary cirrhosis secondary prevention
Primary biliary cirrhosis secondary prevention in the news
Blogs on Primary biliary cirrhosis secondary prevention
Directions to Hospitals Treating Primary biliary cirrhosis
Risk calculators and risk factors for Primary biliary cirrhosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

• Effective measures for the secondary prevention of primary biliary cirrhosis include:
  • Follow up with liver function tests every 3 to 6 months.
  • Follow up with thyroid status annually.
  • Follow up with upper GI endoscopy to assess for development of varices every 2-3 years.
  • Follow up with bone mineral density every 2-4 years, depending upon the baseline density and severity of cholestasis.
  • Follow up with fat-soluble vitamin levels (Vitamin A,D&K) annually in patients with bilirubin >2mg/dl.
  • Follow up with ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma every 6 to12 months among aged men and patients with underlying cirrhosis.